Background: Surveillance scans performed after autologous stem cell transplant (auto-HCT) for patients with Hodgkin disease (HD) have no proven survival benefit. Methods: We studied survival differences among patients with HD after auto-HCT whose recurrences were detected on clinical history and exam, versus those detected on routine surveillance scan. Results: Among the 98 patients with HD that underwent auto-HCT from 2000 to 2014 at our institution, 30 relapsed, of which 21 were detected radiologically and 9 clinically. There were no statistically significant differences in patient characteristics between the 2 groups. The median time to progression was 118 days for the clinical cohort and 284 days for the radiological cohort (p = 0.05). Median overall survival (OS) was 728 days for the clinical cohort, and was not reached for the radiological cohort (p = 0.02). Discussion: In our review, most patients with HD after auto-HCT were diagnosed radiologically. Patients whose relapse was diagnosed clinically were likely to be detected earlier and have a shorter OS. Patients with aggressive disease may be detected when clinically relevant, regardless of scanning. Routine scanning may not be necessary in the majority of patients with HD following auto-HCT.

Keywords:
Autologous stem cell transplant, Hodgkin disease, Surveillance scans, Survival
1.
Siegel R, Ma J, Zou Z, Jemal A: Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
2.
von Tresckow B, Engert A: Refractory Hodgkin lymphoma. Curr Opin Oncol 2013;25:463-469.
3.
Armitage JO: Early-stage Hodgkin's lymphoma. New Engl J Med 2010;363:653-662.
4.
Batlevi CL, Younes A: Novel therapy for Hodgkin lymphoma. Hematol Am Soc Hematol Educ Program 2013;2013:394-399.
5.
Juweid ME: Utility of positron emission tomography (PET) scanning in managing patients with Hodgkin lymphoma. Hematol Am Soc Hematol Educ Program 2006:259-265, 510-511.
6.
Lee AI, Zuckerman DS, van den Abbeele AD, Aquino SL, Crowley D, Toomey C, Lacasce AS, Feng Y, Neuberg DS, Hochberg EP: Surveillance imaging of Hodgkin lymphoma patients in first remission: a clinical and economic analysis. Cancer 2010;116:3835-3842.
7.
Pingali SR, Jewell SW, Havlat L, Bast MA, Thompson JR, Eastwood DC, Bartlett NL, Armitage JO, Wagner-Johnston ND, Vose JM, Fenske TS: Limited utility of routine surveillance imaging for classical Hodgkin lymphoma patients in first complete remission. Cancer 2014;120:2122-2129.
8.
Mocikova H, Obrtlikova P, Vackova B, Trneny M: Positron emission tomography at the end of first-line therapy and during follow-up in patients with Hodgkin lymphoma: a retrospective study. Ann Oncol 2010;21:1222-1227.
9.
Petrausch U, Samaras P, Veit-Haibach P, Tschopp A, Soyka JD, Knuth A, Hany TF, Mischo A, Renner C, Schaefer NG: Hodgkin's lymphoma in remission after first-line therapy: which patients need FDG-PET/CT for follow-up? Ann Oncol 2010;21:1053-1057.
10.
Goldschmidt N, Or O, Klein M, Savitsky B, Paltiel O: The role of routine imaging procedures in the detection of relapse of patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma. Ann Hematol 2011;90:165-171.
11.
Voss SD, Chen L, Constine LS, Chauvenet A, Fitzgerald TJ, Kaste SC, Slovis T, Schwartz CL: Surveillance computed tomography imaging and detection of relapse in intermediate- and advanced-stage pediatric Hodgkin's lymphoma: a report from the Children's Oncology Group. J Clin Oncol 2012;30:2635-2640.
12.
Gandikota N, Hartridge-Lambert S, Migliacci JC, Yahalom J, Portlock CS, Schoder H: Very low utility of surveillance imaging in early-stage classic Hodgkin lymphoma treated with a combination of doxorubicin, bleomycin, vinblastine, and dacarbazine and radiation therapy. Cancer 2015;121:1985-1992.
13.
Jakobsen LH, Hutchings M, de Nully Brown P, Linderoth J, Mylam KJ, Molin D, Johnsen HE, Bogsted M, Jerkeman M, El-Galaly TC: No survival benefit associated with routine surveillance imaging for Hodgkin lymphoma in first remission: a Danish-Swedish population-based observational study. Br J Haematol 2016;173:236-244.
14.
Sodickson A, Baeyens PF, Andriole KP, Prevedello LM, Nawfel RD, Hanson R, Khorasani R: Recurrent CT, cumulative radiation exposure, and associated radiation-induced cancer risks from CT of adults. Radiology 2009;251:175-184.
15.
Brenner DJ, Hall EJ: Computed tomography - an increasing source of radiation exposure. New Engl J Med 2007;357:2277-2284.
16.
Thompson CA, Charlson ME, Schenkein E, Wells MT, Furman RR, Elstrom R, Ruan J, Martin P, Leonard JP: Surveillance CT scans are a source of anxiety and fear of recurrence in long-term lymphoma survivors. Ann Oncol 2010;21:2262-2266.
17.
El-Galaly TC, Mylam KJ, Bogsted M, Brown P, Rossing M, Gang AO, Haglund A, Arboe B, Clausen MR, Jensen P, Pedersen M, Bukh A, Jensen BA, Poulsen CB, d'Amore F, Hutchings M: Role of routine imaging in detecting recurrent lymphoma: a review of 258 patients with relapsed aggressive non-Hodgkin and Hodgkin lymphoma. Am J Hematol 2014;89:575-580.
18.
Engert A, Eichenauer DA, Dreyling M, Group EGW: Hodgkin's lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20(suppl 4):108-109.
19.
National Comprehensive Cancer Network: Hodgkin Lymphoma 2017. Fort Washington, NCCN, 2017.
20.
Ng A, Constine LS, Advani R, Das P, Flowers C, Friedberg J, Hodgson DC, Schwartz CL, Wilder RB, Wilson LD, Yunes MJ: ACR appropriateness criteria: follow-up of Hodgkin's lymphoma. Curr Probl Cancer 2010;34:211-227.
21.
Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V; International Harmonization Project on Lymphoma: Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-586.
22.
Zinzani PL, Stefoni V, Tani M, Fanti S, Musuraca G, Castellucci P, Marchi E, Fina M, Ambrosini V, Pellegrini C, Alinari L, Derenzini E, Montini G, Broccoli A, Bacci F, Pileri S, Baccarani M: Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. J Clin Oncol 2009;27:1781-1787.
23.
El-Galaly TC, Jakobsen LH, Hutchings M, de Nully Brown P, Nilsson-Ehle H, Szekely E, Mylam KJ, Hjalmar V, Johnsen HE, Bogsted M, Jerkeman M: Routine imaging for diffuse large B-cell lymphoma in first complete remission does not improve post-treatment survival: a Danish-Swedish population-based study. J Clin Oncol 2015;33:3993-3998.
24.
Guttikonda R, Herts BR, Dong F, Baker ME, Fenner KB, Pohlman B: Estimated radiation exposure and cancer risk from CT and PET/CT scans in patients with lymphoma. Eur J Radiol 2014;83:1011-1015.
25.
Cohen JB, Behera M, Thompson CA, Flowers CR: Evaluating surveillance imaging for diffuse large B-cell lymphoma and Hodgkin lymphoma. Blood 2017;129:561-564.
26.
Kapke JT, Epperla N, Shah N, Richardson K, Carrum G, Hari PN, Pingali SR, Hamadani M, Karmali R, Fenske TS: Effect of routine surveillance imaging on the outcomes of patients with classical Hodgkin lymphoma after autologous hematopoietic cell transplantation. Clin Lymphoma Myeloma Leuk 2017;17:408-414.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.